Dublin, Jan. 10, 2019 (GLOBE NEWSWIRE) -- The "Global Opioid-Induced Constipation Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The opioid-induced constipation market will register a CAGR of more than 32% by 2022.

Rise in incidence of chronic diseases such as arthritis, back pain, and migraine is likely to drive growth in the market. The incidence of chronic pain is increasing across the world, owing to the several reasons, including lifestyle changes, rise in number of injuries, growth in number of surgeries, and painful medical conditions.

Market Overview

Rise in OIC cases among elderly

Rise in incidences of diseases associated with old age, impaired body functions, and increase in the use of medicines such as antidepressants and anticholinergics have collectively led to high prevalence of constipation among the elderly population. This drives growth in the opioid-induced constipation market.

Use of conventional laxatives for OIC

The use of laxatives for OIC is a major challenge that is reducing sales of approved drugs meant for the treatment of OIC.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Takeda Pharmaceutical and Merck, the competitive environment is quite intense. Factors such as the rise in incidence of chronic diseases such as arthritis, back pain, and migraine and the rise in OIC cases among elderly, will provide considerable growth opportunities to opioid-induced constipation manufactures.

AstraZeneca, Bausch Health, Takeda Pharmaceutical, and Merck are some of the major companies covered in this report.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

• Comparison by application
• Oral
  
• Parenteral
  
• Market opportunity by application

PART 09: MARKET SEGMENTATION BY CLASS OF DRUGS

• Peripherally acting mu-opioid receptor antagonist
• Locally acting chloride channel activator
• Others

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

• Geographical segmentation
• Regional comparison
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

• Rise in incidence of chronic diseases such as arthritis, back pain, and migraine
• Market dominance by opioid receptor antagonists
• Introduction of separate diagnostic guidelines for idiopathic or functional constipation and OIC

PART 15: VENDOR LANDSCAPE

• Landscape disruption

PART 16: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Bausch Health
• Takeda Pharmaceutical
• Merck
  

For more information about this report visit https://www.researchandmarkets.com/research/8dxhnn/global?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastroenterology